Posts Tagged 'drug pipeline'

New Chinese funding source is open for business

New Chinese funding source is open for business

Dynasty Biotechnology is pleased to announce commencement of a major partnership with Cambridge-based Nuformix in a long term, multi-product agreement.

The Nuformix biobetter products fit perfectly within the Dynasty portfolio of China-relevant assets to be developed and commercialised in China and rolled out to non-China markets. “We are delighted to be working with Nuformix and to come to agreement on the first set of assets,” commented Dynasty CEO Dr Simon ...

Continue Reading →
0

Ready, Fire, Aim: pharma’s diagnosis-free growth strategy

Ready, Fire, Aim: pharma’s diagnosis-free growth strategy

So the global pharma and biotech industry still has a pipeline problem: cost per new drug is sky rocketing, volume of new approvals continues to decline, and the influx of likely looking discovery assets is but a trickle. Meanwhile the industry continues to do what it has always done (i.e. implement new team re-structuring or budget allocation ideas), and get what it has always got.

Ready, Fire, Aim?

We still seem to know remarkably little about the drivers governing this pattern. The ...

Continue Reading →
0